NPJ Breast Cancer最新文献

{"title":"Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases.","authors":"Thomas Grinda, Stefania Morganti, Liangge Hsu, Tae-Kyung Yoo, Ross J Kusmick, Ayal A Aizer, Antonio Giordano, Jose P Leone, Melissa Hughes, Sara M Tolaney, Nancy U Lin, Sarah L Sammons","doi":"10.1038/s41523-025-00736-9","DOIUrl":"10.1038/s41523-025-00736-9","url":null,"abstract":"<p><p>Central nervous system (CNS) metastases are associated with poor prognosis in patients with metastatic breast cancer (MBC). In this retrospective study, we investigated the activity of sacituzumab govitecan (SG) in 33 patients with HER2-negative MBC and CNS metastases, including active, stable/treated, and leptomeningeal disease (LMD). SG demonstrated a modest CNS objective response rate of 4/30 (13%) and median CNS-progression-free survival of 2.9 months (95%CI:2.0-4.3) in a heavily pretreated population.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"22"},"PeriodicalIF":6.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer.","authors":"Nina Tamirisa, Wenli Dong, Yu Shen, Heather Lin, Simona F Shaitelman, Gildy Babiera, Isabelle Bedrosian","doi":"10.1038/s41523-025-00732-z","DOIUrl":"10.1038/s41523-025-00732-z","url":null,"abstract":"<p><p>We sought to determine whether sequencing of treatment impacted outcomes in older, comorbid patients. Using the National Cancer Database(2010-2017), 2911 patients >70 with a Charleson Deyo Comorbidity(CCDM) score of 2/3 and cT1c-3/N0-3/HER2 positive or triple-negative breast cancer treated with chemotherapy,surgery,or both were included. Chi-square tests evaluated differences between groups. Multivariable models evaluated associations between overall survival and treatment. Majority 87.4%(n = 2544) underwent surgery first and 36.0%(n = 917) received adjuvant chemotherapy while 77.9%(n = 286) of chemotherapy first patients underwent surgery. Receipt of both modalities was associated with the best survival followed by surgery alone then chemotherapy alone. Additional analysis demonstrated no survival difference between patients who underwent surgery(±systemic therapy) vs systemic therapy(±surgery) first. Although combined treatment offers the best survival, as a single modality, patients treated with surgery vs systemic therapy alone fare better. This information in conjunction with patient preferences on quality of life can be used in making shared decisions.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"21"},"PeriodicalIF":6.5,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype.","authors":"Polina Turova, Vladimir Kushnarev, Oleg Baranov, Anna Butusova, Sofia Menshikova, Sheila T Yong, Anna Nadiryan, Zoia Antysheva, Svetlana Khorkova, Mariia V Guryleva, Alexander Bagaev, Jochen K Lennerz, Konstantin Chernyshov, Nikita Kotlov","doi":"10.1038/s41523-025-00723-0","DOIUrl":"10.1038/s41523-025-00723-0","url":null,"abstract":"<p><p>Current breast cancer classification methods, particularly immunohistochemistry and PAM50, face challenges in accurately characterizing the HER2-low subtype, a therapeutically relevant entity with distinct biological features. This notable gap can lead to misclassification, resulting in inappropriate treatment decisions and suboptimal patient outcomes. Leveraging RNA-seq and machine-learning algorithms, we developed the Breast Cancer Classifier (BCC), a unique transcriptomic classifier for more precise breast cancer subtyping, specifically by delineating and incorporating HER2-low as a distinct subtype. BCC also redefined the PAM50 Normal subtype into other subtypes, disputing its classification as a unique molecular group. Our statistical analysis not only confirmed the reproducibility and accuracy of BCC, but also revealed similarities in prognostic characteristics between the HER2-low and Basal subtypes. Addressing this gap in breast cancer classification is clinically significant because it not only improves treatment stratification, but also uncovers novel molecular and immunohistochemical features associated with the HER2-low and HER2-high subtypes, thereby advancing our understanding of breast cancer heterogeneity and providing guidance in precision oncology.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"19"},"PeriodicalIF":6.5,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal evolution of breast cancer brain metastases treatments and outcomes.","authors":"Michele Bottosso, Gaia Griguolo, Severine Guiu, Maria Cristina Guarascio, Caroline Bailleux, Federica Miglietta, Anna Chiara Cattelan, Christian Zurlo, Jean-Marc Ferrero, Vittoria Aldegheri, Cristina Falci, Francesca Zanghì, Carlo Alberto Giorgi, Alessandro Parisi, Grazia Maria Vernaci, Fabio Girardi, William Jacot, Maria Vittoria Dieci, Amélie Darlix, Valentina Guarneri","doi":"10.1038/s41523-025-00735-w","DOIUrl":"10.1038/s41523-025-00735-w","url":null,"abstract":"<p><p>Brain metastases (BMs) are a common complication of advanced breast cancer (BC), and their management has significantly evolved. We evaluated the clinical impact of these changes dividing patients diagnosed with BCBMs at three Institutions according to year of BMs diagnosis: 2000-2007 (group A), 2008-2014 (group B) and 2015-2022 (group C). Stereotactic radiotherapy increased (p < 0.001), and WBRT decreased (p = 0.010) over time. Among HER2+ BC patients, more received anti-HER2 therapy after BM diagnosis in recent years (p < 0.011). Overall survival (OS) did not improve in the entire cohort (p = 0.260); however, OS improved in patients with HR-/HER2+ BC (median OS 8.7, 10.1, 23.7 months in group A, B, C, respectively; p = 0.002). HER2-positivity, not prognostic in group A, became prognostic in group C (p < 0.001). While therapy for patients with BCBMs significantly changed over two decades, an OS improvement was observed only in HR-/HER2+ patients, potentially due to increased availability of anti-HER2 therapies with intracranial activity.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"20"},"PeriodicalIF":6.5,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer.","authors":"Reiner Hoppe, Stefan Winter, Wing-Yee Lo, Kyriaki Michailidou, Manjeet K Bolla, Renske Keeman, Qin Wang, Joe Dennis, Michael Lush, Krishna R Kalari, Matthew P Goetz, Liewei Wang, Junmei Cairns, Richard Weinshilboum, Lois Shepherd, Bingshu E Chen, Lothar Häberle, Matthias Ruebner, Matthias W Beckmann, Wei He, Nicole L Larson, Sebastian M Armasu, Werner Schroth, Balram Chowbay, Chiea Chuen Khor, Mustapha Abubakar, Antonis C Antoniou, Thomas Brüning, Jose E Castelao, Jenny Chang-Claude, Nbcs Collaborators, Thilo Dörk, Diana M Eccles, Jonine D Figueroa, Manuela Gago-Dominguez, José A García-Sáenz, Melanie Gündert, Carolin C Hack, Ute Hamann, Sileny Han, Maartje J Hooning, Hanna Huebner, Abctb Investigators, Esther M John, Yon-Dschun Ko, Vessela N Kristensen, Sabine Linn, Sara Margolin, Dimitrios Mavroudis, Heli Nevanlinna, Patrick Neven, Nadia Obi, Tjoung-Won Park-Simon, Katri Pylkäs, Muhammad U Rashid, Atocha Romero, Emmanouil Saloustros, Elinor J Sawyer, William J Tapper, Ian Tomlinson, Camilla Wendt, Robert Winqvist, Alison M Dunning, Jacques Simard, Per Hall, Paul D P Pharoah, Matthias Schwab, Fergus J Couch, Kamila Czene, Peter A Fasching, Douglas F Easton, Marjanka K Schmidt, James N Ingle, Hiltrud Brauch","doi":"10.1038/s41523-025-00733-y","DOIUrl":"10.1038/s41523-025-00733-y","url":null,"abstract":"<p><p>The role of germline genetics in adjuvant aromatase inhibitor (AI) treatment efficacy in ER-positive breast cancer is poorly understood. We employed a two-stage candidate gene approach to examine associations between survival endpoints and common germline variants in 753 endocrine resistance-related genes. For a discovery cohort, we screened the Breast Cancer Association Consortium database (n ≥ 90,000 cases) and retrieved 2789 AI-treated patients. Cox model-based analysis revealed 125 variants associated with overall, distant relapse-free, and relapse-free survival (p-value ≤ 1E-04). In validation analysis using five independent cohorts (n = 8857), none of the six selected candidates representing major linkage blocks at CELA2B/CASP9, NR1I2/GSK3B, LRP1B, and MIR143HG (CARMN) were validated. We discuss potential reasons for the failed validation and replication of published findings, including study/treatment heterogeneity and other limitations inherent to genomic treatment outcome studies. For the future, we envision prospective longitudinal studies with sufficiently long follow-up and endpoints that reflect the dynamic nature of endocrine resistance.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"18"},"PeriodicalIF":6.5,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11840073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay.","authors":"Zofia M Komar, Nicole S Verkaik, Ahmed Dahmani, Elodie Montaudon, Roland Kanaar, Adriaan B Houtsmuller, Agnes Jager, Elisabetta Marangoni, Dik C van Gent","doi":"10.1038/s41523-025-00734-x","DOIUrl":"10.1038/s41523-025-00734-x","url":null,"abstract":"<p><p>Breast cancer is the most common cancer amongst women worldwide, however clinically validated chemotherapy response biomarkers that can accurately predict treatment response in patients are largely lacking. Therefore, in this study, functional paclitaxel and eribulin ex vivo sensitivity assays were developed. Patient derived xenograft (PDX) models were used to compare the ex vivo predicted treatment outcome with the sensitivity of mice in vivo. We validated the previously developed sensitivity assay for paclitaxel, which is based on the ratio between replicating (EdU) and mitotic (phospho-Histone H3; pH3) cells as a proxy for blocked mitosis. The assay showed 90% correlation between the ex vivo and in vivo response to paclitaxel treatment in the PDX models. We propose the term REMIT (REplication MITosis) assay and show that it is also a suitable test to predict eribulin sensitivity. The reproducibility of the REMIT assay for paclitaxel and eribulin was determined to be 80% and 83%, respectively. These results justify further clinical validation of the REMIT assay in breast cancer patients.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"17"},"PeriodicalIF":6.5,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11832732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of determinants of breast cancer risk among women with benign breast disease.","authors":"Aileen Burke, Jessica O'Driscoll, Mustapha Abubakar, Kathleen E Bennett, Emma Carmody, Fidelma Flanagan, Gretchen L Gierach, Maeve Mullooly","doi":"10.1038/s41523-024-00703-w","DOIUrl":"10.1038/s41523-024-00703-w","url":null,"abstract":"<p><p>Benign breast disease (BBD) is associated with heterogeneous breast cancer risk. Identifying key breast cancer risk factors for this population may inform breast cancer prevention or early detection strategies. We systematically searched literature databases PubMed, Embase, Scopus, Web of Science, and the Cochrane Library to identify studies reporting associations of demographic, lifestyle, reproductive, and radiological factors with risk of breast cancer among women with biopsy-confirmed BBD. 67 studies met eligibility criteria. Variation was observed for study time period, exposure measurement, comparison groups, outcomes, and adjustment for confounders, precluding meta-analysis. The literature suggested positive risk associations for age at biopsy, family history, mammographic breast density, and time since biopsy, and no association for body mass index, alcohol, smoking, age at menarche, and use of hormonal contraceptives. More research is needed to understand risk factor associations among women with BBD, particularly studies that account for heterogeneity within BBD and breast cancer.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"16"},"PeriodicalIF":6.5,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.","authors":"Rita A Mukhtar, Soumya Gottipati, Christina Yau, Sara López-Tarruella, Helena Earl, Larry Hayward, Louise Hiller, Marie Osdoit, Marieke van der Noordaa, Diane de Croze, Anne-Sophie Hamy, Marick Laé, Fabien Reyal, Gabe S Sonke, Tessa G Steenbruggen, Maartje van Seijen, Jelle Wesseling, Miguel Martín, Maria Del Monte-Millán, Judy C Boughey, Matthew P Goetz, Tanya Hoskin, Vicente Valero, Stephen B Edge, Jean E Abraham, John M S Bartlett, Carlos Caldas, Janet Dunn, Elena Provenzano, Stephen-John Sammut, Jeremy S Thomas, Ashley Graham, Peter Hall, Lorna Mackintosh, Fang Fan, Andrew K Godwin, Kelsey Schwensen, Priyanka Sharma, Angela M DeMichele, Kimberly Cole, Lajos Pusztai, Mi-Ok Kim, Laura J van 't Veer, David Cameron, Laura J Esserman, W Fraser Symmans","doi":"10.1038/s41523-025-00720-3","DOIUrl":"10.1038/s41523-025-00720-3","url":null,"abstract":"<p><p>Residual Cancer Burden (RCB) after neoadjuvant chemotherapy (NAC) is validated to predict event-free survival (EFS) in breast cancer but has not been studied for invasive lobular carcinoma (ILC). We studied patient-level data from a pooled cohort across 12 institutions. Associations between RCB index, class, and EFS were assessed in ILC and non-ILC with mixed effect Cox models and multivariable analyses. Recursive partitioning was used in an exploratory model to stratify prognosis by RCB components. Of 5106 patients, the diagnosis was ILC in 216 and non-ILC in 4890. Increased RCB index was associated with worse EFS in both ILC and non-ILC (p = 0.002 and p < 0.001, respectively) and remained prognostic when stratified by receptor subtype and adjusted for age, grade, T category, and nodal status. Recursive partitioning demonstrated residual invasive cancer cellularity as most prognostic in ILC. These results underscore the utility of RCB for evaluating NAC response in those with ILC.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"14"},"PeriodicalIF":6.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinico-pathological factors predicting pathological response in early triple-negative breast cancer.","authors":"Clara Helal, Lounes Djerroudi, Toulsie Ramtohul, Enora Laas, Anne Vincent-Salomon, Maxime Jin, Romain-David Seban, Ivan Bieche, Diana Bello-Roufai, Francois-Clement Bidard, Paul Cottu, Delphine Loirat, Matthieu Carton, Florence Lerebours, Nicolas Kiavue, Emanuela Romano, Claire Bonneau, Luc Cabel","doi":"10.1038/s41523-025-00729-8","DOIUrl":"10.1038/s41523-025-00729-8","url":null,"abstract":"<p><p>Pathological complete response (pCR) after neoadjuvant chemoimmunotherapy (NACi) is associated with improved patient outcomes in early triple-negative breast cancer (TNBC). This study aimed to identify factors associated with pCR after NACi. This cohort included all patients with stage II-III TNBC treated with NACi who underwent surgery at Institut Curie hospitals between 08/2021-06/2023. Among 208 patients, the overall pCR rate was 70% and was similar in ER < 1% (69%) and ER-low TNBC (73%, p = 0.6). In a multivariate model, Ki-67 ≥ 30% (OR 5.19 [1.73-17.3]), centralized TILs ≥ 30% (OR = 3.08 [1.42-7.04]), absence of DCIS at initial biopsy (OR = 2.56 [1.08-6.25]) and germline mutations in homologous recombination genes (OR = 9.50 [2.37-67.7]) remained strong independent predictors of pCR. These findings may guide treatment decisions in patients with TNBC undergoing NACi. Almost all patients with germline mutations in HR genes achieved pCR, supporting de-escalation trials. We suggest that ER-low tumors should be managed as TNBC tumors.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"15"},"PeriodicalIF":6.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatial proximity of CD8⁺ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer.","authors":"Hongling Liang, Jianqing Huang, Hongsheng Li, Weixing He, Xiang Ao, Zhi Xie, Yu Chen, Zhiyi Lv, Leyao Zhang, Yanhua Zhong, Xiaojun Tan, Guodong Han, Jie Zhou, Ni Qiu, Ming Jiang, Haoming Xia, Yongtao Zhan, Lei Jiao, Jie Ma, Derek Radisky, Jia Huang, Xuchao Zhang","doi":"10.1038/s41523-025-00728-9","DOIUrl":"10.1038/s41523-025-00728-9","url":null,"abstract":"<p><p>The spatial proximity of CD8⁺ T cells to tumor cells critically influences the efficacy of neoadjuvant therapy (NAT) in breast cancer (BC). In this study, we evaluated whether the presence of CD8⁺ T cells and other immune cells near cancer cells predicts treatment outcomes across various BC subtypes. We analyzed pre- and post-NAT biopsies from 104 BC patients using multiplex immunofluorescence (mIF) and immunohistochemistry (IHC) to assess the distribution of immune markers, including CD8⁺ T cells, CD68⁺ macrophages, FoxP3⁺ regulatory T cells. Our findings revealed that a higher percentage of CD8⁺ T cells within 20 µm of cancer cells (N20-CD8⁺ T cells) was strongly correlated with improved pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS), regardless of tumor subtype or NAT regimen. Moreover, a positive correlation between CXCL9 expression and N20-CD8⁺ T cells suggests that CXCL9 may facilitate the recruitment of CD8⁺ T cells to tumor cells. Our study emphasizes the link between immune cell composition and location, and patient outcomes with NAT. Focusing on the spatial dynamics of CD8⁺ T cells could significantly advance personalized treatment strategies and the development of targeted immunotherapies in BC.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"13"},"PeriodicalIF":6.5,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}